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Background: We compared morbidity, mortality, and oncological 
results of bronchial and/or vascular sleeve lobectomy (SL) with those 
of pneumonectomy (PN) after induction therapy for lung cancer.
Methods: Between 1998 and 2011, 82 patients receiving induction 
therapy (chemo or chemo-radiotherapy) for non–small-cell-lung-
cancer underwent sleeve lobectomy (n = 39) or pneumonectomy (n = 
43). Only patients undergoing preoperative chemotherapy (39 in the 
SL group and 39 in the PN group) were included in the study. SL was 
bronchial in 21, vascular in 12, and broncho-vascular in six cases, 
respectively. Clinical stage before induction therapy was IIb in seven 
patients (1 in PN group; 6 in SL group), IIIa in 66 (36 in PN group; 
30 in SL group), and IIIb in five patients (2 in PN group; 3 in SL 
group), respectively. N3 patients were not included in this series.
Results: The rate of downstaged patients (pathological complete 
response and stage I–II) was 79.5% in the SL group and 53.8% in the 
PN group (p = 0.01).Postpneumonectomy mortality rate was 2.6 %. 
There was no postoperative mortality after SL. Complications occurred 
in 12 patients (30.8%) after PN and in 11 patients (28.2%) after SL 
(p = 0.6). Three-year and 5-year survival rates were 68 ± 3% and 64 
± 8% in the SL group; and 59.5 ± 5% and 34.5 ± 8% in the PN group 
(p = 0.02). The difference in terms of recurrence rate (locoregional and 
distant) between the two groups was not significant (p = 0.2).
Conclusions: SL represents a valid therapeutic option even after 
induction chemotherapy, providing better long-term survival than 
PN, with no increase of postoperative complications or recurrence 
rate. Pathological downstaging is a favorable prognostic factor.
Key Words: Induction therapy, Non–small-cell lung cancer, 
Pneumonectomy, Sleeve lobectomy.
(J Thorac Oncol. 2013;8: 637-643)
Lobectomy associated with resection and reconstruction of the bronchus, the pulmonary artery (PA), or both has 
proved to be a valid therapeutic option for the treatment of 
centrally located non–small-cell lung cancer (NSCLC).1 
These are generally accepted operations to avoid pneumo-
nectomy (PN) in patients with compromised cardiac and/or 
pulmonary function, but recent experiences have shown that 
the advantages of sparing lung parenchyma are evident also in 
patients without cardio-pulmonary impairment.2
Moreover, there is clear evidence that sleeve lobectomy 
(SL) is oncologically comparable with PN, with no increased 
postoperative morbidity, lower mortality, and better quality of 
life because of functional preserving (Table 1).3–14 Literature 
studies in this setting generally refer to patients not undergo-
ing preoperative chemotherapy or chemo-radiotherapy, and 
very few data, comparing SL with PN after induction therapy, 
are available.
Although the beneficial effects of neoadjuvant therapy 
on the prognosis of patients with locally advanced lung can-
cer have been largely proven, concern about an increased 
risk of complications, when complex reconstructive proce-
dures are performed after oncological treatment, has limited 
the diffusion of such operations within multimodality treat-
ment options. Tissue damage and fibrotic alterations induced 
by induction therapy may compromise the healing of the 
reconstructed structures, and therefore, are the main techni-
cal aspects influencing the intraoperative and postoperative 
morbidity risk.
In this study, we compare morbidity, mortality, and 
long-term oncological results of lobectomy associated with 
broncho-vascular reconstruction with those of PN after che-
motherapy. Moreover, postoperative outcome of patients 
undergoing sleeve lobectomy after induction treatment is 
compared with that of patients receiving the same operation 
without preoperative treatment.
PATIENTS AND METHODS
Between 1998 and 2011, 82 patients with NSCLC 
underwent bronchial and/or vascular SL (39 patients; 47.6%) 
or PN (43 patients; 52.4%) after induction chemotherapy or 
chemo-radiotherapy. Only patients undergoing preoperative 
chemotherapy (39 in the SL group and 39 in the PN group) 
were included in the study. The four patients receiving 
induction chemo-radiotherapy in the PN group were excluded 
because the preoperative irradiation could represent a factor 
influencing results. Patients undergoing previous surgical 
exploration were not included. We also excluded N3 cases.
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There was no complete correspondence in the 
distribution of the two surgical procedures over time: PN had 
a prevalent distribution in the first part of the study period, 
whereas SL had a prevalent distribution in the second part of 
the study period.
Demographic data and clinical stages before induction 
chemotherapy regimen of the 78 patients included in the study 
are reported in Table 2.
Before surgery, all patients received a three-cycle che-
motherapy regimen consisting of cisplatin–gemcitabine in 
57 cases (72%; SL group: 30; PN group: 27), carboplatin–
vinorelbine in 17 cases (22%; SL group: 7; PN group: 10), 
and cispaltin–paclitaxel in four cases (6%; SL group: 2; PN 
group: 2).
Patients have been classified according to the reviewed 
7th edition of the tumor, node, metastasis clinical and patho-
logical staging system for lung cancer.15 The noninvasive stag-
ing assessment included total body computed tomography 
(CT) scan with contrast medium, fiberoptic bronchoscopy, 
and bone scintigraphy. Magnetic resonance of the brain was 
performed only in patients presenting contraindication for 
contrast medium at CT scan. Fludeoxyglucose positron emis-
sion tomography was performed before the oncological treat-
ment only in those patients with suspected metastatic lesions 
found in CT scan since 2003.
The pulmonary functional assessment was performed by 
spirometry and blood gas analysis; additional functional tests 
such as stress tests and ventilation–perfusion lung scintigra-
phy were performed on patients at risk. Cardiac evaluation 
was routinely performed by electrocardiography; ecocardiog-
raphy was performed for all patients with abnormal electro-
cardiography or previous history of cardiac disease.
All N2 diseases have been histologically or cytologi-
cally proven by mediastinoscopy or transbronchial needle 
aspiration before chemotherapy. The clinical IIIb stage group 
included only T4 N2 tumors.
The indication for induction chemotherapy in the stage 
IIb patients was because of the large size of the primary can-
cer associated with clinical evidence of hilar nodal involve-
ment. A complete clinical restaging was performed after the 
induction treatment and before surgery by whole body CT 
scan with contrast medium and bronchoscopy. In addition, 
since 2004, all patients underwent fludeoxyglucose positron 
emission tomography scan before the operation. The surgical 
technique for sleeve resection and reconstruction of the bron-
chus and the PA has been previously reported.16–18
All the patients underwent operation 3 to 4 weeks after 
the end of induction therapy. We performed a bronchial SL in 
21, a PA SL in 12, and a broncho-vascular SL in six patients, 
respectively. In one case, a right upper bronchial SL was 
TABLE 1.  Literature Data
Author
Patients 
(n)
Complications 
(%)
Mortality 
(%)
L-Recurrence 
(%)
D-Recurrence 
(%)
Stage I  
5-Year 
Survival (%)
Stage II  
5-Year 
Survival (%)
Stage III  
5-Year 
Survival (%)
Overall  
5-Year 
Survival (%)
Gaissert et al.3 SL 72 11 4 14 — — 53 — 42
PN 56 16 9 — — — 43 — 44
Okada et al.4 SL 60 13 2.8 8 — — — — 48
PN 60 22 2 10 — — — — 28
Deslauriers et 
al.5 
SL 184 — 1.6 22 — 66 50 19 52
PN 1046 — 5.3 35 — 50 34 22 31
Bagan et al.7 SL 66 28.8 4.5 4.5 — — — — 72.5
PN 151 29.9 12.6 7.6 — — — — 51.2
Kim et al.8 SL 49 7.4 6.1 22 22 88 52 8 53.7
PN 49 44 4.1 6 20 75 36 38 59.5
Lausberg et al.9 SL 171 0.6a 1.7 36.2 — — — — 45
PN 63 7.9a 6.3 21.3 — — — — 30.4
Ludwig et al.6 SL 116 38 4.3 — — 57 40 22 39
PN 194 26 4.6 — — 45 42 13 27
Takeda et al.10 SL 62 45 4.8 9.7 29 — — — 54.1
PN 110 40.9 3.6 10.9 49.7 — — — 32.9
Parissis et al.12 SL 79 16.4 2.5 17.7 — 75 53 16 46.8
PN 129 21.6 8.5 19.4 — 64 50 18 37.1
Park et al.13 SL 105 29.5 1 14.3 11.4 — — — 58.4
PN 105 33.4 8.6 16.2 21.9 — — — 32.1
Gomez-Caro  
et al.23
SL 55 32 3.6 3.6 38 — — — 61
PN 21 33 5 33 71 — — — 31
Results of studies comparing SL with PN: complications, mortality, recurrence rate, survival.
a Bronchial complications.
D-recurrence, distant recurrence; L-recurrence, locoregional recurrence; SL, sleeve lobectomy; PN, pneumonectomy.
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associated with the superior vena cava resection and recon-
struction by the interposition of a bovine pericardial conduit 
according to the previously described technique.19 In all cases 
of sleeve resection, the bronchial anastomosis was protected 
by an intercostal muscle flap.
Pneumonectomy was on the right in 19 and on the left 
in 20 patients (in 7 cases it was intrapericardial and in 2 cases 
it was associated with en bloc resection of the chest wall). The 
bronchial stump was covered by a vascularized omental flap, 
harvested through the diaphragm in 16 patients considered 
at high risk for bronchial fistula occurrence. The technique 
and indication for the transdiaphragmatic transposition of the 
greater omentum have been previously reported.20
A systematic lymph node dissection was performed in 
all surgical procedures. Operative morbidity and mortality 
were considered within 30 days after surgery.
The oncological follow-up was performed by a total 
body CT scan repeated every 6 months for the first 2 years and 
once a year for the next 3 years. Fiberoptic bronchoscopy was 
performed after 1, 6, and 12 months from surgery, respectively 
and once a year for the next 4 years.
Comparison between Sleeve Lobectomy 
after Induction Therapy and Sleeve 
Lobectomy without Induction Therapy
In the study period (1998–2011), 138 patients (81 men 
and 57 women) underwent SL for NSCLC without induc-
tion therapy. Mean age of the patients was 65 ± 10.2 years 
(range, 45–81). Seventy-five percent of these patients were 
current smokers. The mean preoperative forced expiratory 
volume in 1 second (FEV1) was 84 ± 17% predicted. Sleeve 
resection was bronchial in 87, vascular in 29, and broncho-
vascular in 22 patients. All patients undergoing broncho-
vascular reconstruction presented with clinical stage Ib to 
IIIa-N1.
These patients were considered for comparison with 
those undergoing an SL after induction chemotherapy in the 
same period, to assess whether the preoperative treatment (che-
motherapy) would affect postoperative outcome. Oncological 
results including long-term survival and recurrence rate were 
not compared because of the obvious significant differences 
existing between the two surgical groups (patients with or 
without induction therapy) in terms of tumor staging and type 
of nonsurgical treatment (neoadjuvant and adjuvant therapy).
Statistical Analysis
Data were collected and stored with an Excel database 
(Microsoft Corp, Redmond, WA). Quantitative variables were 
expressed as mean ± SD, whereas nominal variables were 
expressed binarily as presence (1) or absence (0) of the event. 
In the univariate analysis, qualitative variables were analyzed 
with the Pearson c2 test or Fisher’s exact test as required. 
Multivariate analysis was performed by Cox regression on 
variables that showed statistical significance at univariate 
analysis. Survival curves were plotted with the Kaplan–Meier 
formula; the log-rank test was performed to compare survival 
between different groups.
RESULTS
The mean FEV1 after induction therapy and before sur-
gical treatment is reported in Table 2. There was no significant 
difference in terms of preoperative FEV1 between the two sur-
gical groups (p = 0.1).
All patients underwent radical resection with free 
bronchial and vascular margins. Histological findings are 
reported in Table 2. Final pathological stage found in the SL 
group was: stage I in 17 (43.6%), stage II in 10 (25.6%), and 
stage III in eight (20.5%) patients. A complete pathological 
response was observed in four patients (10.3%) of this 
group. Pathological stage in the PN group was: stage I in six 
(15.4%), stage II in 15 (38.5%), and stage III in 18 (46.1%) 
patients. All patients classified as c-stage II in the SL group 
were downstaged as p-stage I after induction therapy. The 
other patients classified as pathological stage I or II, or as 
complete pathological response, presented a clinical stage III 
tumor before induction therapy. The downstaged patients rate 
(complete response, p-stage I–II) was 79.5% in the SL group 
and 53.8% in the PN group (p = 0.01).
Postoperative complications occurred in 13 cases in the 
PN group (33.3%) and in 11 patients undergoing SL (28.2%), 
without statistically significant differences between the two 
groups (p = 0.6). Complications after parenchymal sparing 
operations and PN are reported in Table 3. One patient, pre-
senting late bronchial anastomotic stenosis in the SL group, 
was successfully treated by laser and stenting. The three 
patients experiencing postoperative bleeding in the PN group 
required rethoracotomy. No complications related to the 
vascular reconstruction occurred. One patient died postop-
eratively in the PN group as a result of sepsis after broncho-
pleural fistula (PN group postoperative mortality rate: 2.6%). 
No perioperative mortality was observed in the SL group. 
There was no significant difference in postoperative mortality 
between the two groups (p = 0.3).
TABLE 2.  Patients’ Characteristics
Variable
SL Group  
(n = 39)
PN Group  
(n = 39)
Age (mean, yr ± DS, range) 63 ± 7.8 (47–78) 59.2 ± 10.37 (35–77)
Sex (male/female) 28/11 30/9
Smoke (n, %) 29 (74) 31 (79)
FEV 1a (% predicted ± DS) 88 ± 16 82 ± 21
Histology (n,%)
 Adenocarcinoma 23 (58.9) 11 (28.2)
 Squamous 14 (35.9) 22 (56.4)
 Mixed 1 (2.6) 3 (7.7)
 Large-cell 1 (2.6) 3 (7.7)
Clinical stage before induction  
therapy (n, %)
 IIB 6 (15) 1 (3)
 IIIa 30 (77) 36 (92)
 IIIb 3 (8) 2 (5)
a After induction chemotherapy and before surgical resection.
SL, sleeve lobectomy; PN, pneumonectomy; FEV1, forced expiratory volume in 1 
second.
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The median follow-up was 39 months (range, 2–139) 
(SL group: 37, range, 2–77; PN group: 36, range, 6–139). The 
recurrence rate was 20.5% (n = 8; locoregional 2, distant 6) 
in the SL group and 30.8% in the PN group (n = 12; locore-
gional 1, distant 11), but this difference was not statistically 
significant (p = 0.2). In particular, there was no significant dif-
ference between the two groups, if considering locoregional 
recurrence rate only.
Overall 3- and 5-year survival rates after SL were 
68.3 ± 8% and 64.8 ± 8%, respectively. Overall 3- and 5-year 
survival rates after PN were 59.5 ± 5% and 34.5 ± 8%. The 
difference between the two groups in terms of overall 3-year 
survival was not statistically significant. The difference in 
terms of overall 5-year survival was statistically significant 
(p = 0.02), indicating a better prognosis for the SL group 
(Fig. 1). When considering 5-year survival rate according to 
pathological stages, a significant benefit was found after SL 
for patients with pathological stage I–II or complete response 
(the downstaged tumor patients) (SL group: 80 ± 8% versus 
PN group: 45 ± 7%, p = 0.04) (Fig. 2), whereas no significant 
difference between the two surgical options was reported for 
patients with pathological stage III (the not-downstaged tumor 
patients) (SL group: 25 ± 15% versus PN group: 27 ± 11%, 
p = 0.4). Disease-free (no recurrence) 3- and 5-year survival 
rates were 80 ± 6% and 73 ± 7%, respectively after SL, and 
64.2 ± 7% and 59 ± 10%, respectively after PN (p = 0.1) (Fig. 3). 
Patients who died during the follow-up period because of a 
cause clearly related to the neoplastic disease were six in the 
SL group and 10 in the PN group (p = 0.4).
When considering the whole study population, a sig-
nificant advantage in overall survival was found at univariate 
analysis for the following variables: SL versus PN, no recur-
rence versus recurrence, female versus male sex, preoperative 
FEV1 70% or more predicted versus less than 70% predicted, 
and tumor downstaging (complete response, p-stage I–II) ver-
sus no downstaging (p-stage III) (Table 4). At multivariate 
analysis, only the presence of recurrence, male sex, preopera-
tive FEV1 less than 70% predicted, and pathological stage III 
were confirmed as negative prognostic factors (Table 5).
TABLE 3.  Postoperative Complications after Neoadjuvant 
Chemoterapy
Complication SL (n) PN (n)
Prolonged air leak 5 —
Atrial fibrillation 3 5
BPF–pleural empyema — 2
Bleeding-retoracotomy — 3
Atelectasis 1 1
Pneumonitis 1 —
Bronchial anastomotic stenosis 1 —
Pulmonary edema — 1
Respiratory insufficency — 1
Total 11 13
BPF, broncho-pleural fistula; SL, sleeve lobectomy; PN, pneumonectomy.
FIGURE 1.  Survival curves of patients undergoing sleeve 
lobectomy or pneumonectomy after induction therapy.
FIGURE 2.  Survival curves of p-stage I–II (downstaged) 
patients after sleeve lobectomy or pneumonectomy.
FIGURE 3.  Disease-free survival curves of patients undergo-
ing sleeve lobectomy or pneumonectomy after induction 
therapy.
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Comparison between Sleeve Lobectomy 
after Induction Therapy and Sleeve 
Lobectomy without Induction Therapy
All patients undergoing broncho-vascular reconstruction 
without induction chemotherapy received radical resection 
with free bronchial and vascular margins. Histology was 
adenocarcinoma in 74, squamous cell carcinoma in 57, large-
cell carcinoma in five, and mixed in two patients, respectively. 
Postoperative complications occurred in 32 of these patients 
(23.2%). The most frequent complications were atrial 
fibrillation (9 patients), and parenchymal air leak (7 patients). 
Anastomotic stenosis after bronchial sleeve resection 
occurred in five patients who were successfully treated by 
laser (3 patients) or laser and stenting (2 patients). Other 
complications included pulmonary atelectasis (3 patients), 
wound suppuration (2 patients), pleural empyema (1 patient), 
pneumonitis (1 patient), chest wall hematoma (1 patient), 
phrenic nerve palsy (1 patient), and recurrent nerve palsy (1 
patient). In one patient, a broncho-arterial fistula occurred at 
the anastomotic site, resulting in death. Overall postoperative 
mortality was 0.7% (1 of 138).
The analysis of postoperative complication rates after 
SL did not show significant difference between patients under-
going broncho-vascular reconstruction without induction che-
motherapy and patients receiving preoperative chemotherapy 
(23.2% versus 28.2%; p = 0.5). Similarly there was no sig-
nificant difference in terms of postoperative mortality (0.7% 
versus 0%; p = 0.5).
There was no significant difference between patients 
undergoing direct surgery and patients treated with neoadju-
vant chemotherapy in terms of postoperative intensive care 
unit admission rate (3.6% versus 5.1%; p = 0.67) and post-
operative hospitalization (mean: 7.5 ± 86 days versus 7.8 ± 61 
days; p = 0.07).
DISCUSSION
Sleeve resection for lung cancer is indicated for a tumor 
arising at the origin of a lobar bronchus or at the origin of the 
lobar branches of the PA, but not infiltrating far enough to 
require PN. In addition, a sleeve resection may be indicated 
when N1 nodes infiltrate the bronchus or the PA from the 
outside, and in such cases, a combined reconstruction of the 
bronchus and the PA may be required.
After induction therapy, reconstructive procedures may 
be indicated also when indissociable fibrotic tissue embed 
the PA and/or the bronchus. Oncologically, the primary goal 
in every case is complete resection of the tumor, with free 
resection margins.
Although broncho-vascular reconstructions associated 
with lobectomy represent surgical procedures with higher 
technical complexity when compared with standard major 
lung resections, postoperative morbidity and mortality data 
from a number of recent studies report overall better results 
for patients undergoing SL with respect to PN, especially 
when considering trials published after 2005, indicating the 
achievement of improved outcome with increased experience 
in reconstructive techniques (Table 1).
When analyzing survival data reported in literature over 
the last 20 years, most studies show similar or better results 
for parenchymal sparing resections when compared with PN. 
Moreover, in the analysis of 5-year survival according to stage 
and nodal status, SL results in higher survival rates for stages 
I and II, whereas the survival advantage in stage III seems to 
be limited (Table 1). These results justify the increasing use 
of parenchymal sparing procedures for lung cancer also in 
patients with good cardio-pulmonary function, as observed in 
the last years. Postoperative quality of life has been advocated 
as one of the strongest indicators that should influence the 
decision to perform an SL rather than a PN. A number of stud-
ies indicate that lung parenchyma sparing improves postop-
erative quality of life because of a greater pulmonary reserve. 
Gomez Caro11 and Melloul14 reported a statistically significant 
difference favoring SL in terms of postoperative loss of FEV1.
TABLE 4.  Factors Influencing Long-Term Survival, According 
to Univariate Analysis
Variable ±95% p OR
Surgery (PN/SL) 0.007 3.441 1.379–8.587
Side (R/L) 0.517 0.750 0.314–1.791
Recurrence (yes/no) 0.0001 20.956 5.484–80.081
Complications (yes/no) 0.446 1.448 0.558–3.759
Smoke (yes/no) 0.166 0.484 0.172–1.365
Heart disease (yes/no) 0.356 1.545 0.611–3.906
Age (yrs) (≥65/<65) 0.109 2.575 0.749–12.022
Sex (male/female) 0.001 8.077 2.150–30.339
FEV1 (%) (<70/≥70) 0.001 5.700 1.963–16.633
Histology (squamous/ 
nonsquamous)
0.727 1.169 0.486–2.812
Downstaging (no/yes) 0.002 4.321 1.637–11.405
L, left; OR, odds ratio; PN, pneumonectomy; R, right; SL, sleeve lobectomy; FEV1, 
forced expiratory volume in 1 second.
TABLE 5.  Factors Influencing Long-Term Survival, According 
to Multivariate Analysis (Cox Regression)
Variables in the Equation p OR
95.0% CI for 
Exp(B)
Lower Upper
Surgery (PN/SL) 0.481 0.719 0.287 1.801
Side (R/L) 0.240 1.562 0.742 3.288
Recurrence (yes/no) 0.007 0.359 0.172 0.751
Complications (yes/no) 0.912 0.952 0.395 2.292
Smoke (yes/no) 0.524 1.358 0.531 3.474
Heart disease (yes/no) 0.925 0.959 0.403 2.280
Age (yrs) (≥65/<65) 0.698 0.754 0.181 3.135
Sex (M/F) 0.027 0.232 0.064 0.848
FEV1 (%) (<70/≥70) 0.017 0.389 0.179 0.845
Histology (squamous/ 
nonsquamous)
0.125 0.489 0.196 1.218
Downstaging (no/yes) 0.044 0.442 0.200 0.977
CI, confidence interval; L, left; OR, odds ratio; PN, pneumonectomy; R, right; SL, 
sleeve lobectomy; FEV1, forced expiratory volume in 1 second.
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Induction chemotherapy represents a standardized 
indication for advanced-stage NSCLC patients because this 
treatment modality has been proven to allow improved local 
and systemic tumor control and survival benefit.21,22 However, 
the administration of a neoadjuvant therapy has been fre-
quently reported as a factor significantly increasing the risk 
for postoperative complications and mortality, although some 
recent prospective studies have demonstrated the possibility 
of performing major lung surgery safely even after induction 
treatment.23
The occurrence of complications can be related to 
technical reasons in the surgical management because of 
the anatomical alterations and tissue damage produced by 
the oncological treatment in the operative field. Moreover, 
the detrimental effect of chemotherapy on lung parenchyma, 
predisposing to acute respiratory distress syndrome and 
pneumonia, has to be considered.
In many experiences, the postoperative risk after induc-
tion therapy has been found to be significantly increased 
when a PN, especially on the right side, is performed.24 The 
mortality rate after right PN after induction therapy has been 
reported between 14% and 43% in recent large series.21,22,25 
In the Southwest Oncology Group S9900 trial,22 a 16.7% 
mortality rate has been reported in the PN group after induc-
tion chemotherapy in comparison with no mortality in the 
surgery-alone group. Worse results have been observed with 
the associated administration of preoperative irradiation. In 
a phase III trial by Albain et al.21, analyzing the role of sur-
gery after chemotherapy plus radiotherapy, a 26% operative 
mortality was registered after PN, leading to the conclusion 
that trimodality treatment may be beneficial if PN can be 
avoided.
Bronchial stump insufficiency with consequent bron-
cho-pleural fistula and pleural empyema, and acute respiratory 
distress syndrome of the residual lung have been reported as 
the most frequent postpneumonectomy complications result-
ing in death, in main series analyzing risk factors for surgical 
morbidity and mortality after neoadjuvant therapy.
Very limited data are available in the literature when 
considering broncho-vascular reconstructions after induc-
tion therapy. Only few experiences have been published so far 
reporting the routine use of sleeve resection after neoadjuvant 
therapy.23,26–30
Although we along with other authors23,26–28,30 have 
proved in the past years the possibility of performing even 
complex broncho-vascular reconstructive procedures after 
induction therapy with short-term and long-term results com-
parable with those of the standard procedures, special concern 
has been expressed by many thoracic surgeons when consider-
ing such operations because of the theoretically higher risk of 
perioperative complications and mortality. Scarring tissue and 
desmoplastic reaction produced by the neoadjuvant treatment 
generally increases the technical difficulty of bronchial and 
vascular hilar dissection and may be responsible for impaired 
bronchial healing, thus providing additional problems when 
performing a reconstructive procedure. It is interesting to 
note that in this study we have showed that patients undergo-
ing SL after neoadjuvant chemotherapy report no significant 
difference in terms of postoperative morbidity and mortality 
when compared with those undergoing this operation without 
induction treatment.
To the best of our knowledge, no published large experi-
ence is actually available in the literature comparing short-term 
and long-term results of SL with those of PN after induction 
therapy. This study reports a trend toward lower morbidity and 
mortality rates in SL patients in comparison with PN patients 
receiving preoperative chemotherapy, although no significant 
difference was found.
Moreover, we have observed a significantly higher 
5-year survival rate in patients undergoing broncho-vascular 
reconstruction with respect to those undergoing PN. This 
seems to be principally a result of the higher rate of patients 
showing response to therapy in the SL group (79% versus 
53%) and also because at multivariate analysis, tumor down-
staging has been found to be a significant factor influencing 
prognosis.
Moreover, a favorable impact on long-term survival 
because of the parenchymal sparing and consequent improved 
cardio-pulmonary status cannot be excluded. This positive 
effect on prognosis related to the better postoperative perfor-
mance status is suggested by the lack of difference in disease-
free survival rates between SL patients and PN patients found 
in this study. This indicates that the rate of patients surviv-
ing without recurrence is similar between the two groups, 
and therefore, better long-term prognosis observed after 
parenchymal sparing operations may not be justified only by 
oncological reasons. Furthermore, the number of patients who 
died during the follow-up period as a result of causes clearly 
related to neoplastic recurrence was lower in the SL group 
when compared with the PN group, although the difference 
was not significant.
When considering the theoretical increased bronchial 
healing complications incidence (bronchial stump insuffi-
ciency after a PN and anastomotic dehiscence after an SL) 
because of the effects of preoperative treatment on bronchial 
tissue, a significant reduction of this risk can be achieved by 
the systematic use of vascularized flaps.20,24
We routinely perform a protection (intercostals muscle 
flap) of the bronchial anastomotic line after an SL, and we 
consider this procedure as one of the key factors to the low 
anastomotic dehiscence rate observed in our experience even 
after induction therapy.
Similarly, over the last 15 years, we have standardized 
the use of viable tissue flaps, usually greater omentum, in 
patients undergoing PN after induction therapy considered 
at significantly increased risk for bronchial dehiscence, with 
the aim of reinforcing the bronchial stump.20 This techni-
cal strategy has proved effective because no occurrence of 
broncho-pleural fistula has been observed in patients treated 
with this technique, and both the patients experiencing post-
pneumonectomy broncho-pleural fistula in this series were 
operated in the early period of this study without the omental 
flap bronchial reinforcement because of technical or general 
contraindication for the omentoplasty procedure. The use of 
the greater omentum has been preferred to the muscular flap 
in PN patients as it provides a larger amount of tissue and a 
643Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 5, May 2013 Sleeve Lobectomy Compared with Pnuemonectomy after Induction Therapy
rich vascular supply, assuring adequate oxygen and antibiotic 
delivery. Both these aspects may prove advantageous after 
PN, when an empty pleural cavity is present and the risk of 
empyema is higher. Moreover, the well-known immunologic 
action of the omentum may play a role in the prophylaxis of 
postpneumonectomy pleural infection.
A limitation of this study is represented by the 
nonhomogeneous induction therapy regimen administered, 
including different pharmacological options. However, 
because of the similar distribution of the different oncological 
therapeutic regimens between the two groups of patients (PN 
group and SL group), we think that this aspect is unlikely 
to influence the results. Another issue to be considered is 
related to the criteria used for the decision to perform an 
SL or a PN. These are principally based on tumor extent 
and intraoperative surgeon’s judgment, and therefore, could 
represent a theoretical bias. Patients with larger tumors are 
more likely to receive a PN. This aspect may justify the 
higher rate of downstaged tumors among patients undergoing 
broncho-vascular reconstruction. Moreover, we have observed 
a higher rate of squamous cell carcinoma in the PN patients; 
this finding may have influenced the response to the induction 
chemotherapy in this group.
In conclusion, SL represents a valid therapeutic option 
even after induction chemotherapy, providing better long-term 
survival than PN, with no increase of postoperative complica-
tions and recurrence rate. Pathological downstaging is a favor-
able prognostic factor.
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